Cover Image

Cost-effectiveness of empagliflozin for the treatment of heart failure: a systematic review

Objective: This study aims to synthesize evidence on the cost-effectiveness of empagliflozin for heart failure (HF).Methods: MEDLINE, Embase, the Cochrane Library, EconLit, CNKI, Wanfang Data and Chongqing VIP were searched to identify original articles on cost-effectiveness of empagliflozin for HF,...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jinyu Liu (Author), Dong Liu (Author), Xuepeng Gong (Author), Anhua Wei (Author), Ruxu You (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review
by: Jinyu Liu, et al.
Published: (2022)

Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland
by: Hallinen T, et al.
Published: (2023)

Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China
by: Yi Tang, et al.
Published: (2022)

Progress of patients hospitalized with acute heart failure treated with empagliflozin
by: Manuel Raya-Cruz, et al.
Published: (2024)

Empagliflozin-A New Chance for Patients with Chronic Heart Failure
by: Klaudia Kowalska, et al.
Published: (2021)

Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
by: Erik Håkansson, et al.
Published: (2021)

Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022)

Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia
by: Siew Chin Ong, et al.
Published: (2023)

Glyceraldehyde derivatives inspired by empagliflozin as potential anti-heart failure agents independent of glucose-lowering effects
by: Xiao Li, et al.
Published: (2024)

Cost effectiveness analyses of pharmacological treatments in heart failure
by: Audrey Huili Lim, et al.
Published: (2022)

Clinical Efficacy and Safety of Empagliflozin in Patients with Acute Heart Failure from the First Day of Hospitalization
by: D. P. Golubovskaya, et al.
Published: (2023)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024)

Identification of Key Immune-Related Genes in the Treatment of Heart Failure After Myocardial Infarction with Empagliflozin Based on RNA-Seq
by: Zhang P, et al.
Published: (2023)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023)

Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China
by: Jinyu Liu, et al.
Published: (2021)

Cost-Effectiveness of Sequential Teriparatide/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
by: Ruxu You, et al.
Published: (2022)

Integration of RNA-Seq and Machine Learning Identifies Hub Genes for Empagliflozin Benefitable Heart Failure with Reduced Ejection Fraction
by: Yang Q, et al.
Published: (2023)

Cost-Effectiveness of Sequential Denosumab/Zoledronic Acid Compared With Zoledronic Acid Monotherapy for Postmenopausal Osteoporotic Women in China
by: Ruxu You, et al.
Published: (2022)

Readmission Risk Prediction Model for Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis
by: Jing Liu, et al.
Published: (2022)

Cost-Effectiveness of Zoledronic Acid Versus Oral Alendronate for Postmenopausal Osteoporotic Women in China
by: Ruxu You, et al.
Published: (2020)

Effects of Empagliflozin on Gut Microbiota in Heart Failure with a Preserved Ejection Fraction: The Design of a Pragmatic Randomized, Open-Label Controlled Trial (EMPAGUM)
by: Guan XQ, et al.
Published: (2023)

CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
by: Ghetti G, et al.
Published: (2023)

Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure
by: Jaehong Kim, et al.
Published: (2024)

Costs and cost-effectiveness of treatment setting for children with wasting, oedema and growth failure/faltering: A systematic review.
by: Noreen Dadirai Mdege, et al.
Published: (2023)

Costs and cost-effectiveness of treatment setting for children with wasting, oedema and growth failure/faltering: A systematic review
by: Noreen Dadirai Mdege, et al.
Published: (2023)

Sacubitril-valsartan versus enalapril for the treatment of acute decompensated heart failure in Chinese settings: A cost-effectiveness analysis
by: Tianyang Hu, et al.
Published: (2023)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
by: Shubrook JH, et al.
Published: (2015)

Combination of Empagliflozin and Liraglutide protects heart against isoproterenol-induced myocardial infarction in rats
by: Neng Fisheri Kurniati, et al.
Published: (2023)

Cost-effectiveness of Empagliflozin Compared to Liraglutide in Iran Based on Cardiovascular Outcome Trials in Type 2 Diabetes Mellitus
by: Nayyereh Ayati, et al.
Published: (2022)

Effectiveness of eHealth Self-management Interventions in Patients With Heart Failure: Systematic Review and Meta-analysis
by: Siru Liu, et al.
Published: (2022)

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
by: Krittayaphong R, et al.
Published: (2019)

Cost-utility analysis of add-on vericiguat for the treatment of chronic heart failure with reduced ejection fraction in China
by: Lu Wang, et al.
Published: (2024)

Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review
by: Meiyu Wu, et al.
Published: (2022)

Predicting costs of care in heart failure patients
by: Smith David H, et al.
Published: (2012)

Effectiveness of nurse-led heart failure clinic: A systematic review
by: Xiaoxiao Wu, et al.
Published: (2024)

Cost-Effectiveness of Cardiac Resynchronization Therapy in Patients with Heart Failure in Thailand
by: Permsuwan U, et al.
Published: (2020)

Economic Evaluation of Oral Alendronate Therapy for Osteoporosis in Chinese Postmenopausal Women: The Impact of Medication Compliance and Persistence
by: Ruxu You, et al.
Published: (2020)

The effects of thiamine supplementation on patients with heart failure: A systematic review and meta-analysis of randomized controlled trials
by: Mengqi Xu, et al.
Published: (2022)

Systematic review: Telehealth in the Patients Management with Heart Failure
by: Citra Indra Gustian, et al.
Published: (2023)

Efficacy and Safety of TCMI in Patients With Combined Coronary Heart Disease and Heart Failure: A Systematic Review and Network Meta-Analysis
by: Penglu Wei, et al.
Published: (2021)